All FDA-approved EMA-approved PMDA-approved
Target Card Uniprot Example: P23975

romiplostim 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definition	Drug id	CAS RN
colony stimulating factors	4996	267639-76-9

Description:

Molecule

Description

Synonyms: romiplostim nplate AMG-531 AMG531

Romiplostim, a member of the TPO mimetic class, is an Fc-peptide fusion protein (peptibody) that activates intracellular transcriptional pathways leading to increased platelet production via the TPO receptor (also known as cMpl). The peptibody molecule contains two identical single-chain subunits, each consisting of human immunoglobulin IgG1 Fc domain, covalently linked at the C-terminus to a peptide containing two thrombopoietin receptor-binding domains. Romiplostim has no amino acid sequence homology to endogenous TPO. Romiplostim is produced by recombinant DNA technology in Escherichia coli. Molecular weight: Formula: CLOGP: LIPINSKI: None HAC: None HDO: None TPSA: ALOGS: ROTB: None

Drug dosage:

Dose	Unit	Route
30	mcg	P

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

None

Approvals:

Date	Agency	Company	Orphan
Jan. 21, 2011	PMDA	Kyowa Hakko Kirin
Aug. 22, 2008	FDA	AMGEN
Feb. 4, 2009	EMA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Platelet count abnormal	1942.63	20.53	365	13546	3970	90610566
Platelet count decreased	1567.31	20.53	636	13275	136333	90478203
Therapeutic response decreased	1059.33	20.53	427	13484	89302	90525234
Thrombocytopenia	649.33	20.53	401	13510	208324	90406212
Thrombocytosis	524.07	20.53	136	13775	6865	90607671
Platelet count increased	404.19	20.53	143	13768	20716	90593820
Myelofibrosis	321.88	20.53	69	13842	1498	90613038
Petechiae	320.52	20.53	112	13799	15629	90598907
Splenectomy	294.53	20.53	55	13856	570	90613966
Drug ineffective	279.24	20.53	635	13276	1383663	89230873
Haemorrhage	260.80	20.53	151	13760	69218	90545318
Biopsy bone marrow abnormal	240.39	20.53	41	13870	239	90614297
Bone marrow reticulin fibrosis	202.27	20.53	34	13877	179	90614357
Death	193.71	20.53	290	13621	456261	90158275
Immune thrombocytopenia	190.19	20.53	73	13838	13253	90601283
Myelodysplastic syndrome	164.77	20.53	75	13836	20828	90593708
Deep vein thrombosis	153.90	20.53	121	13790	91499	90523037
Purpura	132.38	20.53	58	13853	14720	90599816
Epistaxis	123.02	20.53	103	13808	85022	90529514
Off label use	111.83	20.53	396	13515	1101856	89512680
Gingival bleeding	97.43	20.53	47	13864	14856	90599680
Hospitalisation	95.91	20.53	108	13803	127992	90486544
Mucosal haemorrhage	93.23	20.53	25	13886	1428	90613108
Evans syndrome	90.81	20.53	19	13892	365	90614171
Chronic lymphocytic leukaemia	81.95	20.53	27	13884	3143	90611393
Drug effective for unapproved indication	80.52	20.53	34	13877	7884	90606652
Pulmonary embolism	79.25	20.53	99	13812	130721	90483815
Vaginal haemorrhage	79.17	20.53	53	13858	31218	90583318
Therapy non-responder	77.35	20.53	100	13811	136604	90477932
Ecchymosis	66.15	20.53	34	13877	12289	90602247
Contusion	59.66	20.53	124	13787	251092	90363444
Haemorrhage intracranial	59.54	20.53	34	13877	15128	90599408
Mucocutaneous haemorrhage	59.34	20.53	11	13900	109	90614427
Cerebral venous sinus thrombosis	56.49	20.53	19	13892	2357	90612179
Mouth haemorrhage	56.13	20.53	27	13884	8474	90606062
Cerebral haemorrhage	54.49	20.53	44	13867	34478	90580058
Heavy menstrual bleeding	52.45	20.53	35	13876	20495	90594041
Bone marrow disorder	51.96	20.53	19	13892	3013	90611523
Cerebral venous thrombosis	49.03	20.53	17	13894	2311	90612225
Infusion related reaction	49.02	20.53	4	13907	416776	90197760
Drug hypersensitivity	48.08	20.53	7	13904	463602	90150934
Melaena	47.95	20.53	41	13870	34756	90579780
Leukocytosis	47.85	20.53	39	13872	30951	90583585
Product preparation error	45.71	20.53	25	13886	10236	90604300
Thrombosis	45.23	20.53	56	13855	73195	90541341
Acute myeloid leukaemia	45.20	20.53	32	13879	20608	90593928
Joint swelling	44.97	20.53	11	13900	503289	90111247
Haematological malignancy	44.51	20.53	11	13900	453	90614083
Rheumatoid arthritis	44.00	20.53	3	13908	362611	90251925
Gastrointestinal haemorrhage	43.36	20.53	61	13850	90187	90524349
White blood cell count increased	39.27	20.53	50	13861	67191	90547345
Leukoerythroblastic anaemia	38.13	20.53	6	13905	19	90614517
Aplastic anaemia	37.26	20.53	24	13887	13245	90601291
Portal vein thrombosis	37.07	20.53	15	13896	3123	90611413
Arthropathy	36.88	20.53	6	13905	366236	90248300
Headache	36.77	20.53	242	13669	862504	89752032
Product use issue	36.57	20.53	4	13907	329915	90284621
Chronic myelomonocytic leukaemia	35.60	20.53	9	13902	407	90614129
Splenomegaly	35.36	20.53	23	13888	12901	90601635
Abdominal discomfort	34.60	20.53	15	13896	477313	90137223
Antiphospholipid syndrome	34.38	20.53	13	13898	2261	90612275
Swelling	34	20.53	11	13900	419047	90195489
Platelet disorder	33.92	20.53	13	13898	2346	90612190
Occupational exposure to product	33.03	20.53	13	13898	2518	90612018
Wound	32.76	20.53	4	13907	302976	90311560
Drug intolerance	32.54	20.53	14	13897	447577	90166959
Bone pain	31.42	20.53	43	13868	61940	90552596
Embolism	31.28	20.53	19	13892	9462	90605074
Embolism arterial	30.80	20.53	10	13901	1111	90613425
Pericarditis	30.64	20.53	3	13908	270148	90344388
Toxicity to various agents	30.63	20.53	4	13907	287842	90326694
Marrow hyperplasia	30.24	20.53	9	13902	750	90613786
Musculoskeletal stiffness	29.53	20.53	5	13906	296527	90318009
Cerebrovascular accident	29.30	20.53	61	13850	123472	90491064
Sudden hearing loss	28.46	20.53	10	13901	1413	90613123
Refusal of treatment by patient	28.41	20.53	15	13896	5723	90608813
Peripheral swelling	28.35	20.53	14	13897	413092	90201444
Lower respiratory tract infection	27.87	20.53	3	13908	250656	90363880
Blood blister	27.40	20.53	11	13900	2244	90612292
Reticulin increased	27.08	20.53	4	13907	7	90614529
Stomatitis	26.55	20.53	5	13906	274693	90339843
Rash maculo-papular	26.40	20.53	32	13879	40901	90573635
Hypersensitivity	26.16	20.53	19	13892	454658	90159878
Rectal haemorrhage	25.94	20.53	46	13865	82698	90531838
Anaemia	25.90	20.53	115	13796	352687	90261849
Sepsis	25.68	20.53	73	13838	179741	90434795
Impaired healing	25.54	20.53	3	13908	234196	90380340
Haemoglobin decreased	25.35	20.53	68	13843	161888	90452648
Antibody test	25.34	20.53	4	13907	13	90614523
Hepatic enzyme increased	25.09	20.53	12	13899	360724	90253812
Intercepted product administration error	24.63	20.53	8	13903	890	90613646
Haematoma	24.33	20.53	30	13881	39018	90575518
Blood smear test abnormal	24.10	20.53	5	13906	92	90614444
Pain	24.00	20.53	76	13835	996265	89618271
Condition aggravated	23.91	20.53	34	13877	595511	90019025
Blister	23.89	20.53	5	13906	254993	90359543
Drug ineffective for unapproved indication	23.45	20.53	39	13872	66605	90547931
Megaloblasts increased	23.35	20.53	3	13908	0	90614536
HCoV-OC43 infection	23.07	20.53	4	13907	26	90614510
Myeloproliferative neoplasm	22.73	20.53	7	13904	655	90613881
Myalgia	22.05	20.53	68	13843	175057	90439479
Bone marrow myelogram abnormal	21.73	20.53	4	13907	38	90614498
Intercepted product preparation error	21.61	20.53	8	13903	1312	90613224
Non-Hodgkin's lymphoma	21.23	20.53	8	13903	1378	90613158
Type 2 diabetes mellitus	21.20	20.53	3	13908	203241	90411295
Ovarian cancer	20.90	20.53	13	13898	6754	90607782
Dyspnoea	20.64	20.53	68	13843	880887	89733649

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Platelet count abnormal	1085.70	20.17	244	12180	3405	42605506
Platelet count decreased	822.33	20.17	506	11918	138075	42470836
Therapeutic response decreased	776.00	20.17	319	12105	36693	42572218
Drug ineffective	351.14	20.17	640	11784	629557	41979354
Platelet count increased	321.64	20.17	120	12304	10583	42598328
Bone marrow reticulin fibrosis	318.74	20.17	53	12371	111	42608800
Thrombocytosis	282.76	20.17	89	12335	4686	42604225
Coombs positive haemolytic anaemia	252.59	20.17	61	12363	1174	42607737
Thrombocytopenia	252.43	20.17	293	12131	189986	42418925
Myelodysplastic syndrome	225.98	20.17	117	12307	22628	42586283
Lymphadenitis	209.68	20.17	61	12363	2450	42606461
Myelofibrosis	190.89	20.17	53	12371	1794	42607117
Haemolysis	161.65	20.17	71	12353	9518	42599393
Splenectomy	155.67	20.17	34	12390	409	42608502
Therapeutic product effect decreased	153.32	20.17	111	12313	39039	42569872
Petechiae	149.61	20.17	69	12355	10366	42598545
Immune thrombocytopenia	144.86	20.17	69	12355	11147	42597764
Biopsy bone marrow abnormal	133.84	20.17	28	12396	270	42608641
Haematological malignancy	131.30	20.17	31	12393	539	42608372
Hospitalisation	116.16	20.17	125	12299	74205	42534706
Death	105.37	20.17	338	12086	470847	42138064
Migraine	85.89	20.17	66	12358	25348	42583563
Haemorrhage	84.47	20.17	96	12328	60467	42548444
Deep vein thrombosis	82.89	20.17	107	12317	76850	42532061
Acute myeloid leukaemia	82.31	20.17	61	12363	22195	42586716
Chronic lymphocytic leukaemia	78.92	20.17	35	12389	4794	42604117
Therapy non-responder	78.54	20.17	87	12337	53272	42555639
Migraine with aura	75.27	20.17	22	12402	897	42608014
Off label use	69.69	20.17	367	12057	637968	41970943
Epistaxis	64.37	20.17	88	12336	66738	42542173
Drug interaction	56.66	20.17	6	12418	266993	42341918
Investigation	53.55	20.17	17	12407	918	42607993
Hepatic enzyme increased	52.96	20.17	66	12358	45718	42563193
Toxicity to various agents	51.69	20.17	4	12420	229132	42379779
Gingival bleeding	49.89	20.17	31	12393	8454	42600457
Mouth haemorrhage	47.60	20.17	27	12397	6234	42602677
Ecchymosis	47.30	20.17	29	12395	7723	42601188
Contusion	46.13	20.17	59	12365	41926	42566985
Embolism arterial	42.82	20.17	14	12410	831	42608080
Pulmonary embolism	42.54	20.17	102	12322	119510	42489401
Cellulitis gangrenous	38.13	20.17	10	12414	271	42608640
Bone marrow disorder	37.70	20.17	16	12408	1970	42606941
Infusion related reaction	37.28	20.17	65	12359	60741	42548170
Platelet disorder	36.30	20.17	16	12408	2158	42606753
Myeloproliferative neoplasm	35.57	20.17	12	12412	785	42608126
Evans syndrome	33.92	20.17	10	12414	420	42608491
Cerebrovascular accident	33.61	20.17	82	12342	97078	42511833
Condition aggravated	30.80	20.17	19	12405	260735	42348176
Mesenteric vascular insufficiency	30.55	20.17	7	12417	106	42608805
Antiphospholipid syndrome	30.21	20.17	10	12414	617	42608294
Marrow hyperplasia	29.96	20.17	12	12412	1275	42607636
Therapeutic response delayed	28.87	20.17	10	12414	709	42608202
Non-Hodgkin's lymphoma	28.61	20.17	12	12412	1435	42607476
Reticulin increased	28.56	20.17	4	12420	0	42608911
Mucocutaneous haemorrhage	28.44	20.17	7	12417	146	42608765
Thrombocytopenia neonatal	27.29	20.17	9	12415	549	42608362
Diarrhoea	27.02	20.17	59	12365	460790	42148121
Mucosal haemorrhage	26.15	20.17	12	12412	1778	42607133
Embolism	25.81	20.17	21	12403	8742	42600169
Refusal of treatment by patient	25.35	20.17	17	12407	5274	42603637
Thrombosis	24.95	20.17	59	12365	68452	42540459
Vomiting	24.58	20.17	29	12395	289694	42319217
Product preparation error	24.46	20.17	16	12408	4762	42604149
Bone pain	23.89	20.17	32	12392	23760	42585151
Intercepted product administration error	23.37	20.17	8	12416	547	42608364
Hypotension	22.70	20.17	25	12399	257606	42351305
Acute kidney injury	22.36	20.17	46	12378	367291	42241620
Lymphoma	22.17	20.17	24	12400	14297	42594614
Dyspnoea	21.77	20.17	62	12362	442559	42166352
Gastrointestinal haemorrhage	21.49	20.17	70	12354	97656	42511255
Splenosis	21.42	20.17	3	12421	0	42608911
Leukocytosis	21.19	20.17	34	12390	29674	42579237
White blood cell count increased	21.15	20.17	43	12381	45044	42563867
Protein-losing gastroenteropathy	21.05	20.17	7	12417	438	42608473
Chronic myelomonocytic leukaemia	20.89	20.17	8	12416	755	42608156
Neutropenia	20.36	20.17	113	12311	199318	42409593
Dehydration	20.23	20.17	8	12416	141759	42467152

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Platelet count abnormal	2271.17	17.71	453	19321	5829	110563696
Platelet count decreased	1634.85	17.71	802	18972	229641	110339884
Thrombocytosis	723.58	17.71	197	19577	10247	110559278
Therapeutic response decreased	720.50	17.71	349	19425	96150	110473375
Thrombocytopenia	597.44	17.71	495	19279	348390	110221135
Platelet count increased	481.33	17.71	180	19594	26154	110543371
Petechiae	370.73	17.71	144	19630	23173	110546352
Myelofibrosis	360.07	17.71	88	19686	2963	110566562
Bone marrow reticulin fibrosis	298.30	17.71	52	19722	294	110569231
Drug ineffective	282.61	17.71	744	19030	1519796	109049729
Coombs positive haemolytic anaemia	267.36	17.71	61	19713	1516	110568009
Haemorrhage	243.74	17.71	180	19594	106512	110463013
Myelodysplastic syndrome	236.13	17.71	121	19653	37363	110532162
Biopsy bone marrow abnormal	228.71	17.71	44	19730	458	110569067
Splenectomy	210.24	17.71	45	19729	825	110568700
Off label use	203.68	17.71	657	19117	1499528	109069997
Immune thrombocytopenia	197.05	17.71	91	19683	22403	110547122
Lymphadenitis	191.93	17.71	61	19713	5432	110564093
Deep vein thrombosis	171.79	17.71	165	19609	139722	110429803
Haemolysis	171.33	17.71	74	19700	15565	110553960
Epistaxis	164.30	17.71	156	19618	130216	110439309
Death	140.92	17.71	354	19420	698515	109871010
Therapy non-responder	131.27	17.71	151	19623	157156	110412369
Gingival bleeding	127.68	17.71	65	19709	19774	110549751
Purpura	120.51	17.71	67	19707	24321	110545204
Hospitalisation	105.99	17.71	129	19645	142364	110427161
Pulmonary embolism	98.78	17.71	154	19620	214320	110355205
Therapeutic product effect decreased	98.33	17.71	165	19609	244151	110325374
Evans syndrome	94.81	17.71	23	19751	749	110568776
Mucosal haemorrhage	87.08	17.71	29	19745	2991	110566534
Mouth haemorrhage	83.33	17.71	43	19731	13445	110556080
Drug effective for unapproved indication	81.34	17.71	43	19731	14124	110555401
Ecchymosis	75.86	17.71	44	19730	17294	110552231
Acute myeloid leukaemia	73.08	17.71	58	19716	38052	110531473
Contusion	72.66	17.71	141	19633	233220	110336305
Vaginal haemorrhage	70.33	17.71	48	19726	25026	110544499
Mucocutaneous haemorrhage	70.02	17.71	15	19759	276	110569249
Haematological malignancy	69.71	17.71	19	19755	988	110568537
Toxicity to various agents	61.53	17.71	7	19767	480548	110088977
Product preparation error	59.58	17.71	32	19742	10847	110558678
Investigation	57.84	17.71	20	19754	2312	110567213
Migraine with aura	57	17.71	22	19752	3470	110566055
Antiphospholipid syndrome	56.30	17.71	20	19754	2503	110567022
Platelet disorder	55.91	17.71	22	19752	3653	110565872
Marrow hyperplasia	54.80	17.71	18	19756	1778	110567747
Cerebral haemorrhage	53.51	17.71	62	19712	64906	110504619
White blood cell count increased	52.34	17.71	75	19699	96767	110472758
Gastrointestinal haemorrhage	51.48	17.71	100	19674	165418	110404107
Cerebral venous thrombosis	51.29	17.71	20	19754	3242	110566283
Cerebral venous sinus thrombosis	49.98	17.71	19	19755	2876	110566649
Drug interaction	49.62	17.71	14	19760	500169	110069356
Leukocytosis	48.81	17.71	54	19720	53774	110515751
Chronic lymphocytic leukaemia	48.70	17.71	23	19751	5945	110563580
Drug hypersensitivity	48.33	17.71	11	19763	454079	110115446
Joint swelling	46.59	17.71	11	19763	442834	110126691
Haemorrhage intracranial	44.94	17.71	39	19735	28930	110540595
Melaena	44.32	17.71	58	19716	68699	110500826
Bone pain	43.64	17.71	56	19718	65077	110504448
Cerebrovascular accident	42.95	17.71	98	19676	181186	110388339
Condition aggravated	41.69	17.71	42	19732	734794	109834731
Drug ineffective for unapproved indication	40.70	17.71	69	19705	102769	110466756
Reticulin increased	40.28	17.71	6	19768	9	110569516
Leukoerythroblastic anaemia	39.89	17.71	6	19768	10	110569515
Neutralising antibodies positive	39.78	17.71	10	19764	378	110569147
Cellulitis gangrenous	38.85	17.71	10	19764	416	110569109
Product use issue	38.74	17.71	5	19769	311690	110257835
Splenomegaly	38.04	17.71	33	19741	24465	110545060
Autoimmune haemolytic anaemia	36.38	17.71	23	19751	10544	110558981
Wheezing	34.52	17.71	3	19771	255227	110314298
Migraine	34.42	17.71	87	19687	171565	110397960
Headache	34.25	17.71	272	19502	882105	109687420
Dyspnoea	33.46	17.71	95	19679	1106777	109462748
Haemorrhagic diathesis	32.70	17.71	19	19755	7489	110562036
Drug intolerance	32.55	17.71	16	19758	406496	110163029
Mesenteric vascular insufficiency	32.26	17.71	7	19767	137	110569388
Megakaryocytes increased	32.22	17.71	7	19767	138	110569387
Peripheral swelling	32.21	17.71	16	19758	404018	110165507
Blood blister	31.88	17.71	15	19759	3844	110565681
Vomiting	31.47	17.71	73	19701	910602	109658923
Myeloproliferative neoplasm	30.83	17.71	11	19763	1394	110568131
Arthropathy	30.50	17.71	7	19767	287515	110282010
Neutropenia	30.33	17.71	140	19634	374480	110195045
Swelling	29.36	17.71	13	19761	351028	110218497
Thrombosis	28.26	17.71	61	19713	108601	110460924
Intercepted product administration error	27.66	17.71	9	19765	863	110568662
Bone marrow disorder	27.64	17.71	14	19760	4209	110565316
Musculoskeletal stiffness	27.41	17.71	8	19766	279814	110289711
Heavy menstrual bleeding	27.36	17.71	23	19751	16342	110553183
Therapeutic response delayed	27.20	17.71	10	19764	1380	110568145
Upper respiratory tract inflammation	27.18	17.71	14	19760	4357	110565168
Abdominal discomfort	26.60	17.71	19	19755	393839	110175686
Wound	26.32	17.71	5	19769	234432	110335093
Haemolytic anaemia	26.24	17.71	25	19749	20895	110548630
Anti-platelet antibody positive	26.08	17.71	7	19767	343	110569182
Pain	25.95	17.71	86	19688	954869	109614656
Sudden hearing loss	25.71	17.71	11	19763	2258	110567267
Lower respiratory tract infection	25.62	17.71	6	19768	243100	110326425
Dry mouth	25.35	17.71	3	19771	199945	110369580
Antibody test	25.23	17.71	4	19770	11	110569514
Cerebral infarction	24.91	17.71	38	19736	51800	110517725
Intercepted medication error	24.73	17.71	9	19765	1207	110568318
Paroxysmal nocturnal haemoglobinuria	24.72	17.71	7	19767	419	110569106
Chronic myeloid leukaemia	24.61	17.71	13	19761	4260	110565265
Conjunctival haemorrhage	24.25	17.71	15	19759	6618	110562907
Refusal of treatment by patient	23.87	17.71	17	19757	9477	110560048
Red blood cell abnormality	23.52	17.71	8	19766	880	110568645
Embolism	23.41	17.71	21	19753	16268	110553257
Portal vein thrombosis	23.40	17.71	15	19759	7043	110562482
Blister	23.21	17.71	6	19768	227370	110342155
Bone marrow myelogram abnormal	23.09	17.71	5	19769	97	110569428
Hypersensitivity	22.98	17.71	23	19751	403975	110165550
Megakaryocytes abnormal	22.58	17.71	5	19769	108	110569417
Pruritus	22.24	17.71	44	19730	581516	109988009
Chronic myelomonocytic leukaemia	22.11	17.71	8	19766	1055	110568470
Sepsis	21.96	17.71	116	19658	327230	110242295
Neutralising antibodies	21.74	17.71	4	19770	32	110569493
Type 2 diabetes mellitus	21.64	17.71	3	19771	177229	110392296
Leukoerythroblastosis	21.53	17.71	6	19768	339	110569186
Diarrhoea	21.49	17.71	118	19656	1139387	109430138
Intercepted product preparation error	21.39	17.71	14	19760	6806	110562719
Aplastic anaemia	21.37	17.71	24	19750	24284	110545241
Anaemia	21.35	17.71	169	19605	546917	110022608
Rectal haemorrhage	21.22	17.71	58	19716	119775	110449750
Unevaluable event	21.16	17.71	38	19736	59189	110510336
Stomatitis	21.08	17.71	11	19763	270231	110299294
Ischaemic stroke	20.89	17.71	31	19743	41232	110528293
Haemoglobin decreased	20.89	17.71	94	19680	248633	110320892
Fibromyalgia	20.62	17.71	3	19771	170906	110398619
Neoplasm malignant	20.40	17.71	29	19745	37114	110532411
Osteoarthritis	20.28	17.71	4	19770	182619	110386906
Haematoma	20.23	17.71	37	19737	58439	110511086
HCoV-OC43 infection	19.76	17.71	4	19770	55	110569470
Megaloblasts increased	19.59	17.71	3	19771	6	110569519
Antibody test positive	19.42	17.71	10	19764	3110	110566415
Sinusitis	19.14	17.71	15	19759	296673	110272852
Oxygen saturation decreased	18.38	17.71	3	19771	156979	110412546
Asthma	18.35	17.71	11	19763	250280	110319245
Platelet production decreased	18.27	17.71	3	19771	11	110569514
Bradycardia	18.14	17.71	3	19771	155514	110414011
Platelet glycoprotein gene mutation	18.06	17.71	3	19771	12	110569513
Hypotension	18.05	17.71	42	19732	523807	110045718
Acute leukaemia	17.82	17.71	8	19766	1841	110567684

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	B02BX04	BLOOD AND BLOOD FORMING ORGANS ANTIHEMORRHAGICS VITAMIN K AND OTHER HEMOSTATICS Other systemic hemostatics
FDA MoA	N0000175968	Thrombopoietin Receptor Agonists
FDA PE	N0000175969	Increased Megakaryocyte Maturation
FDA PE	N0000175970	Increased Platelet Production
FDA EPC	N0000175973	Thrombopoietin Receptor Agonist
CHEBI has role	CHEBI:35610	antineoplastic agent
CHEBI has role	CHEBI:75835	anti-anaemic agent

Related Drugs by ATC class:

B02BX Other systemic hemostatics 10 drugs

avatrombopagcarbazochromeconcizumabeltrombopagemicizumabetamsylatefitusiranfostamatiniblusutrombopagmarstacimab-hncq

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Chronic idiopathic thrombocytopenic purpura	indication	13172003
Aplastic anemia	indication	306058006	DOID:12449

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Thrombopoietin receptor	Membrane receptor	P40238	TPOR_HUMAN	AGONIST				DRUG LABEL	DRUG LABEL

External reference:

ID	Source
D08990	KEGG_DRUG
4028106	VUID
N0000177934	NUI
4028106	VANDF
CHEBI:749606	CHEBI
CHEMBL1201832	ChEMBL_ID
C488777	MESH_SUPPLEMENTAL_RECORD_UI
6974	IUPHAR_LIGAND_ID
DB05332	DRUGBANK_ID
805452	RXNORM
147787	MMSL
25808	MMSL
d07320	MMSL
012794	NDDF
439122000	SNOMEDCT_US
441077008	SNOMEDCT_US
C2364481	UMLSCUI
8587	INN_ID
135449332	PUBCHEM_CID
GN5XU2DXKV	UNII

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Nplate	HUMAN PRESCRIPTION DRUG LABEL	1	55513-221	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	250 ug	SUBCUTANEOUS	BLA	31 sections
Nplate	HUMAN PRESCRIPTION DRUG LABEL	1	55513-222	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	500 ug	SUBCUTANEOUS	BLA	31 sections
Nplate	HUMAN PRESCRIPTION DRUG LABEL	1	55513-223	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	125 ug	SUBCUTANEOUS	BLA	31 sections